Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Prevention of Transfusion-Transmitted Malaria By Treatment of Whole Blood with the Mirasol ® PRT System

Jean-Pierre Allain, MD PhD, Alex Owusu-Ofori, PhD, Sonny Michael Assennato, MS, Susanne Marschner, PhD, Raymond P Goodrich, PhD, Shirley Owusu-Ofori, MBChB

Blood (2015) 126 (23): 770.

https://doi.org/10.1182/blood.V126.23.770.770

Published: 2015

Journal Articles

Adherence of Stored Apheresis Platelets (PLTs) with and without Pathogen Reduction Treatment (PRT) to Collagen in a Microfluidic Flow Chamber

Daniel R. Ambruso, MD, Ryan Seewald, BA, Jorge A Dipaola, MD, Gary Brodsky, PhD, Susanne Marschner, PhD, Raymond P. Goodrich, PhD

Blood (2012) 120 (21): 1179.

https://doi.org/10.1182/blood.V120.21.1179.1179

Published: 2012

Journal Articles

Expression of Platelet (PLT) P-Selectin and PLT-Neutrophil (PMN) Interaction After Treatment of Whole Blood with Mirasol ® PRT.

Daniel R. Ambruso, MD, Ryan Seewald, BA, Susanne Marschner, PhD, Raymond P. Goodrich, PhD

Blood (2012) 120 (21): 2288.

https://doi.org/10.1182/blood.V120.21.2288.2288

Published: 2012

Journal Articles

Prevention of Alloimmunization and Induction of Partial Tolerance Following Transfusion with Pathogen Reduced Platelets in Mice

Rachael P. Jackman, Marcus O. Muench, John W. Heitman, Susanne Marschner, PhD, Raymond P. Goodrich, PhD, Philip J. Norris

Blood (2011) 118 (21): 718.

https://doi.org/10.1182/blood.V118.21.718.718

Published: 2011

Journal Articles

Expression of P-Selectin and Platelet-Neutrophil (PMN) Interactions In Untreated and Mirasol ® PRT Treated Platelet Concentrates During Routine Storage.

Daniel R Ambruso, MD, Raymond P Goodrich, PhD, Susanne Marschner, PhD

Blood (2010) 116 (21): 1123.

https://doi.org/10.1182/blood.V116.21.1123.1123

Published: 2010

Journal Articles

Impact of Pathogen Reduction Technology Treatment and Storage in New Generation Platelet Additive Solutions (PAS) on Platelet Function.

Gines Escolar, MD, PhD, Miguel Lozano, MD, PhD, Patricia Molina, Susanne Marschner, Ph.D., Raymond Goodrich, PhD, Ana M. Galan, Ph.D.

Blood (2009) 114 (22): 2115.

https://doi.org/10.1182/blood.V114.22.2115.2115

Published: 2009

Journal Articles

Inactivation of Human Leukocytes in Platelet Products After Pathogen Reduction Technology Treatment in the Presence of Platelet Additive Solution.

Loren D. Fast, PhD, Susanne Marschner, Ph.D., Gilbert DiLeone, Ph.D., Raymond Goodrich, PhD

Blood (2009) 114 (22): 2116.

https://doi.org/10.1182/blood.V114.22.2116.2116

Published: 2009

Journal Articles

Mirasol™ Pathogen Reduction of Packed Red Blood Cells (PRBCs) and Apheresis Platelet (Aplt) Concentrates Decreases Neutrophil Priming Activity Generated during Storage.

Daniel R. Ambruso, Gail Thurman, Susanne Marschner, Ray Goodrich

Blood (2007) 110 (11): 2893.

https://doi.org/10.1182/blood.V110.11.2893.2893

Published: 2007

Journal Articles

Inactivation of Human White Blood Cells in Red Blood Cell Products Using the MIRASOL® System for Whole Blood.

Loren D. Fast, PhD, Susanne Marschner, Ph.D., Gilbert DiLeone, Ph.D., Suzann Doane, B.S., Christy Fitzpatrick, B.S., Goodrich Ray, Ph.D.

Blood (2007) 110 (11): 2897.

https://doi.org/10.1182/blood.V110.11.2897.2897

Published: 2007

Journal Articles

Inactivation of Human White Blood Cells in Red Blood Cell Products Using Mirasol® Pathogen Reduction Technology (PRT).

Loren D. Fast, PhD, Susanne Marschner, Ph.D., Gilbert DiLeone, Ph.D., Suzann K. Doane, B.S., Raymond P. Goodrich, Ph.D.

Blood (2006) 108 (11): 4135.

https://doi.org/10.1182/blood.V108.11.4135.4135

Published: 2006

Journal Articles

Prevention of Alloimmunization to Platelets and Cardiac Transplants by Mirasol‚ Pathogen Reduction Technology (PRT).

Hiroshi Asano, MD, PhD, Chih-Yuan Lee, MD, William M. Baldwin, MD, PhD, Susanne Marschner, PhD, Raymond Goodrich, PhD

Blood (2006) 108 (11): 944.

https://doi.org/10.1182/blood.V108.11.944.944

Published: 2006

Journal Articles

CXCR4 engagement is required for HIV-1–induced L-selectin shedding

JiangFang Wang, Susanne Marschner, Terri H. Finkel

Blood (2004) 103 (4): 1218–1221.

https://doi.org/10.1182/blood-2003-02-0576

Published: 2004

Includes: Supplemental data

NARROW

Prevention of Transfusion-Transmitted Malaria By Treatment of Whole Blood with the Mirasol ® PRT System

Adherence of Stored Apheresis Platelets (PLTs) with and without Pathogen Reduction Treatment (PRT) to Collagen in a Microfluidic Flow Chamber

Expression of Platelet (PLT) P-Selectin and PLT-Neutrophil (PMN) Interaction After Treatment of Whole Blood with Mirasol ® PRT.

Prevention of Alloimmunization and Induction of Partial Tolerance Following Transfusion with Pathogen Reduced Platelets in Mice

Expression of P-Selectin and Platelet-Neutrophil (PMN) Interactions In Untreated and Mirasol ® PRT Treated Platelet Concentrates During Routine Storage.

Impact of Pathogen Reduction Technology Treatment and Storage in New Generation Platelet Additive Solutions (PAS) on Platelet Function.

Inactivation of Human Leukocytes in Platelet Products After Pathogen Reduction Technology Treatment in the Presence of Platelet Additive Solution.

Mirasol™ Pathogen Reduction of Packed Red Blood Cells (PRBCs) and Apheresis Platelet (Aplt) Concentrates Decreases Neutrophil Priming Activity Generated during Storage.

Inactivation of Human White Blood Cells in Red Blood Cell Products Using the MIRASOL® System for Whole Blood.

Inactivation of Human White Blood Cells in Red Blood Cell Products Using Mirasol® Pathogen Reduction Technology (PRT).

Prevention of Alloimmunization to Platelets and Cardiac Transplants by Mirasol‚ Pathogen Reduction Technology (PRT).

CXCR4 engagement is required for HIV-1–induced L-selectin shedding

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only